A new drug targeted at preventing the recurrence of liver cancer after it is treated surgically is expected to receive approval in most Asian countries by 2015, according to the company authorized to develop, produce and market the drug.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Cross-Strait
Taiwan protests China's expanded use of controversial flight paths
04/19/2024 08:19 PM - Politics
New minister of environment to roll out carbon pricing roadmap
04/19/2024 07:12 PM - Business
Think tank raises Taiwan 2024 GDP growth to 3.38% amid export optimism
04/19/2024 05:33 PM - Politics
Premier-designate Cho picks labor, health, environment ministers (update)
04/19/2024 04:26 PM - Business
U.S. dollar closes sharply higher on Taipei forex market
04/19/2024 04:11 PM